# Continuous or Intermittent Extension of Adjuvant Pyrotinib for Invasive HER2-positive Breast Cancer

> **NCT05910398** · PHASE3 · RECRUITING · sponsor: **RenJi Hospital** · enrollment: 488 (estimated)

## Conditions studied

- Breast Cancer Invasive

## Interventions

- **DRUG:** pyrotinib

## Key facts

- **NCT ID:** NCT05910398
- **Lead sponsor:** RenJi Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-06-01
- **Primary completion:** 2030-04
- **Final completion:** 2030-08
- **Target enrollment:** 488 (ESTIMATED)
- **Last updated:** 2025-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05910398

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05910398, "Continuous or Intermittent Extension of Adjuvant Pyrotinib for Invasive HER2-positive Breast Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05910398. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*